Peritoneal Cancer Clinical Trial
Official title:
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
Phase 2 single arm open label study to evaluate the combination of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer. Approximately 15 subjects will be screened to enroll approximately 10 evaluable subjects. The study will include: - Screening period up to 28 days prior to start of study treatment. - Treatment period up to 24 weeks. - Post-treatment follow-up period: - Safety Follow-up: all subjects will be followed at least 30 days after end of treatment for safety. - Long Term Follow-up: all subjects will be followed for survival approximately every 3 months for 1 year, until death, withdrawal of consent, lost to follow-up, or sponsor decision to close the study; or whichever comes first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04983550 -
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
|
Phase 2 | |
| Completed |
NCT01610206 -
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT00768144 -
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
|
Phase 2 | |
| Completed |
NCT00801320 -
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
N/A | |
| Suspended |
NCT00753480 -
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
| Recruiting |
NCT02349958 -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
|
Phase 2 | |
| Completed |
NCT00268918 -
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
|
Phase 1 | |
| Completed |
NCT00230542 -
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT00461786 -
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
|
Phase 2 | |
| Terminated |
NCT00505661 -
Letrozole in Patients With Ovarian Tumors
|
Phase 2 | |
| Completed |
NCT02865811 -
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
|
Phase 2 | |
| Recruiting |
NCT05009082 -
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
|
Phase 3 | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT01891344 -
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
|
Phase 2 | |
| Recruiting |
NCT05887609 -
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
|
Phase 2 | |
| Active, not recruiting |
NCT02470299 -
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
|
N/A | |
| Recruiting |
NCT06184867 -
Choices About Genetic Testing And Learning Your Risk With Smart Technology
|
Early Phase 1 | |
| Recruiting |
NCT04516447 -
A Study of ZN-c3 in Patients With Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT04088786 -
Phase I Trial HIPEC With Nal-irinotecan
|
Phase 1 |